Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/20
Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020GlobeNewsWire • 07/28/20
Will Paratek Pharmaceuticals (PRTK) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/28/20
Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of StockholdersGlobeNewsWire • 05/29/20
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/20
Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)GlobeNewsWire • 03/10/20
Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price GainsSeeking Alpha • 03/05/20
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China RegionGlobeNewsWire • 02/24/20
Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?Zacks Investment Research • 12/20/19
Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain24/7 Wall Street • 12/19/19
BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 202024/7 Wall Street • 12/19/19